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three cases, in onc patient mixed culture with S. aureus, in one with S. aureus
and K. pneumoniae. Three patients were treated with penicillin without
clinical succes. Finally, all were treated with clindamycin: 900 mg/day (1
patient), lBOO mg/day (2), 2700 mg/day (2). Four patients were cured and
one female died ofcirculatory arrest in 13. day ofhospitalisatioD despite local
improvement.
Conclusion: We found clindamycin as first-line drug in invasive S. pyo-
genes infections. It should be ordered in case ofSTSS in high doses from 1800
to 2700 mg/day or above.
IWeP281I First case of meningitis due to penidllin-resistant
Streptococcus pneumonlae (PRSP). In Greece
S. Pentea, S. Kanavaki, S. Karabela, M. Macarona, S. Eustathiou, A.
Pefanis
3rd Department ofMedicine, Athens University MedKal Sthool; Microbiology
D~parl~mmt, "Sotiria" Gmnal Hospital, Ath~ns, Grcec~
ObjectIves: To present the first adult case of meningitis due to PRSP in
Greece.
The case: A 74-year old female patient, with a previous history of non-
Hodgkin's lymphoma, was admitted to the hospital because of fever,
headache and vomiting started 24 hours before admission. PRSP was
isolated from cultures of both CSF and blood. The MICs of the PRSP
strain were as follows: penicillin > 2 IJg/mJ, cefuiaxone > 1 J-tg/mJ,
cefotaxime > 2 IJg/ml, chloramphenicol < 2 lJg/ml, imipenem < 0.06
IJg/ml, and vancomycin < 1 J-tg/ml (Vitec II, bioMerieux, France). By using
the E-test method, the MIC of penicillin was found to be > 3 IJg/ml.
Despite the fact, empirical treatment with ceftriaxone (2 g x 2, iv),
vancomycin (1 g x 2, iv), rifabin (600 mg x I, iv), and dexamethasone (0.4
mg/kg x 2, iv) was started immediately, the patient died one week after
admission to the hospital.
Conclusions: Although, the incidence of infections due to PRSP in some
European countries is high, it still remains quite low in Greece. The isolation
from CSF, for the first time, of a PRSP strain, warrants a change in the
recommended empirical treatment regimen for adult meningitis. The
addition of rifabin or vancomycin to ceftriaxone seems to be a reasonable
choice for adult patients with 0 a Gram-stain of CSF indicative for S.
pneumonia~.
IWeP282I Extraintestinal amoebiasis - An emerging parasitic
infection
Manuela Curescu
Clinic of Infectious Dis~as~s, Univmity ofM~dici~ and Pharmacy Timisoara,
Romania
Objectives: Clinical presentation ofextraintestinal amoebiases, with several
pulmonar abscesses and splenic abscess.
Methods: The author presents the clinical case of the patient M.P., 56 years,
from the district of Arad, Romania, with the following symptoms of
disease: abrupt onset with shivering and septic fever, cough with muco-
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IMo0201 AUCIMIC bl'llakpoints of rnoxifloxadn (MOX)
...Iative to levofloxacln (LEV) predicted with in vitro dynamic
models: Single dose versus multiple dose simulations
A. Firsovt, S. Zinner2, S. Vostrovl , I. Lubenkol
'Cmtr~for Science & T~chnology LeItBioT~ch, Moscow, Russian Federation;
ZMount Auburn Hospital, Harvard Medical School, Cambridg~, MA, Unit~d
States
Objectives: To elucidate if single dose pharmacokinetic simulations can
establish AUC/MIC breakpoints.
Methods: The pharmacodynamics of MOX and LEV were studied by
simulating their single and multiple (once-daily dosing for three days) dose
administration. With both single and multiple dosing, a methicillin-resistant
purulent expectoration and, occasionally hemoptysia, wasting syndrome (15
kg weight loss), respiratory impairment and toxemia. The radiologic
examination shows several opacities with large dimensions in both lungs.
After antibiotic therapy with third generation ofcephalosporins, the clinical
signs and the radiologic aspects are unmodified. The performed bronho-
scopy is followed in few hours by vomica with discharging of brown.
chocolate-like pus. The native microscopical examination of the bronchial
aspirate and of the expectoration shows extremely frequent clusters of
vegetative, magna forms, ofEntamoeba histolytica. Abdominal echography
and computertomography confirme the presence of a splenic abscess, with-
out involving the liver and the central nervous system. There were either
epidemiologic argumentations nor other cases ofinfections with Entamoeba
histolytica in the teritory.
Results: After two cures of treatment with the combination hidroxiclor-
oquine + metronidazole, the author succeeded the sterilization of the
pulmonar abscesses with the tendency of normalization of the radiologic
aspect and the disparition of the splenic abscess.
Conclusions: Extraintestinal amoebiases is nowadays not only a tropical
disease and physicians can be confronted with diagnose difficulties, if a
singular case appears in Central Europe.
IWeP283! Rapid progression of medically controlled ce...br.1
cystic echinococcosis
S. Reuter, P. Kern
S~ction ofInf~ctiousDis~ases, University Hospital of Ulm, Gumany
Objectives: We present a rapidly progredient case of cystic cerebral echi-
nococcosis of the brain under current medication with albendazole.
Methods: The patient had been followed in our outpatient department for
more than 5 years. He had been first operated in 1993 and had not been
treated with benzimidazoles postoperatively. In 1996 he was reoperated due
to a relapse and had been on continuous albendazole-treatment since.
Results: He now presented with headaches, adynamy, right-sided
exophthalmos and a fistula in the area of the right eyebrow.
A CCT during a routine visit 4 weeks earlier had been inconspicuous and
he now had two new hypodense structures of6 x 4 cm and 1.5 x 1 em in the
right frontal hemisphere with thin, ringlike contrast enhancement. Histol-
ogy revealed the typical germinal layer of Echillococcus granulosus with no
signs of bacterial superinfection. .
Both structures were resected without opening. Postoperatively, alben-
dazole treatment (BOO mg/d) was complemented by praziquantel (750 mgJ
d). Despite a large operative defect the neurologic symptoms completely
normalized over the next six months.
Conclusions: Postoperative medical treatment in cystic echinococcosis is
generally restricted to 3 months and is usually parasitocidal. In the present
case, long-term treatment was initiated after a relapse 3 years ago. Despite
coverage with benzimidazoles the patient now developed another relapse.
Compliance was reliable and we may assume that either cerebral drug levels
were insufficient to kill the parasite or that prolonged treatment promoted
drug-resistance. As a therapeutic alternative to benzimidazoles praziquantel
was started and has been well tolerated for 5 months.
isolate ofStaphylococcus aureus (MICMOX 0.37 J-tg/ml and MICLEV 0.61J8/
mJ) was exposed to monoexponentially decreasing concentrations ofMOX
and LEV with the half-lives of12 and 6.8 h, respectively, over a 4-fold dose/
MIC ranges that provided the AUC/MIC ratios from 120 to 500 h.
Results: The total antimicrobial effect as expressed by the IE parameter
correlated well with log AUC/MIC (single dose experiments) and mean log
AUC/MIC determined over the 24 h dosing interval (AUC24 h/MIC -
multiple dose experiments) in a quinolone specific fashion. A given AUC/
MIC or AUC24 h/MIC ratio of MOX produced greater IEs than LEV. In
single dose studies, the AUC/MIC breakpoints of MOX and LEV, (the
AUC/MICs that are equivalent to 125-h AUC/MIC of ciprofloxacin) were
80 and 130 h, respectively. The latter value correspond. to a LEV AUC24 hI
MIC of120. In multiple dose studies, this AUC24 h/MIC was equivalent to
6O-h AUC24 h/MIC ofMOX that is equivalent to 8O-h AUC/MIC. Thus,
the AUC/MIC breakpoints of MOX relative to LEV established in single
and multiple dose experiments were almost identical (SO h).
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Condusions: Single dose studies are highly predictive of dose-response
relationships in multiple dose studies.
IMo021j Pharmacokinetics. metabolism. and exaetion of 14C_
ZIRAON (evemimidn) in healthy male volunteers
c. Banfield, P. Krieter, M. Thonoor, N. Blumenkratz,]. Patrick, M.
Cayen
Schering-Plough Research Institute, Kenilworth, Nj, United States
Objectives: ZIRACIN (evemimicin) has demonstrated superior in vitro
and in vivo activity against all Gram-positive bacteria testcd and has been
shown in clinical trials to be effective in the rreatment of Srreptococcus
pneumonia<: pneumonia. This study evaluated the pharmacokinetics (PK),
metabolism, and excretion of radiolabeled evemimicin.
Methods: 6 healthy male volunteers, aged 21-44 yrs, received 437 mg/75
p.Ci 14C-evernimicin (ca. 6 mg/kg) IV over I-hr. Blood, urine, and fecal
samples were collected before and serially up to 168 hrs after infusion. Parent
compound concentrations were determined using HPLC-VV; metabolites
were profiled by HPLC with radiometric detection and LCfMS; radio-
activity concenrrations were determined by liquid scintillation spectroscopy.
PK parameters were calculated using noncompartmental methods.
Results: PK: Serum and blood concentrations of 14C-derived evemimicin
were highest immediately following infusion and declined rapidly followed
by a gradual elimination. The parent compound was 58% of the serum
radioactivity, indicating the presence of metabolites. Excretion: Approxi-
mately 50% and 41 % ofthe radioactive dose was eliminated in the urine and
feces, respectively accounting for 91 % of the total dose that was recovered
over 7-days. Approximately 6% ofthe dose was recovered unchanged in the
urine. Metabolism: The main modes ofmetabolism ofl4C-evernimicin were
the formation of sulfate and glucuronic acid conjugates and hydrolysis/
degradation of the parent compound.
Condusion: Evemimicin is metabolized mainly by formation of glucuro-
nide and sulfate conjugates.
IMo022ISingle dose PK of ZIRAON (evemimidn) in renal
insuciency
C. Banfield, S. Pai, L. Lambrecht, M. Laughlin, M. Affrime
Schering-Plough Research Institute, Kenilworth, Nj, United States
Objectives: The PK of ZIRACIN (evemimicin) (ZIR) in patients with
chronic renal impairment (CRI) was evaluated.
Methods: An open-label, parallel group study in healthy male and female
volunteers, (31-73 yrs), divided into groups (n = 4/grp) based on creatinine
clearance (CrCl), who received a single 3 mgfkg dose ofZIR. Categories for
CrCl were: normal (~80);mild (~5O-79);mod (~3O-49);severe (~15-29);
and dialysis « IS). Serum and urine samples were collected at predose, and
serially 48-hrs postdose. Concentrations ofZIR were determined by HPLC
for Cm • x , AVC, total body clearance (CL) and Vdss.
Results
Parameter Normal Mild Mod Severe Dialysis
Cmax(Jlg/mL) 44.8 57.3 48.4 46.6 43.9
AUCoc (Jlg hr/mL) 119 162 135 127 127
T 1J2"tr(hr) 8.34 8.52 9.83 9.12 9.74
CL (mL/hr/kg) 25.5 18.6 22.2 24.5 25.6
Vdss (mL/kg) 237 184 280 279 320
The similarities in mean AVC and mean clearance rates for all 5 CRI
groups show that CRI did not significantly alter the PK of ZIR.
ConclusIons: ZIR is safe and well tolerated following a single 3 mg/kg dose
in patients with CRI and does not appear to require dosage adjustments.
IMo023IPharmacokinetic and pharmacodynamic
investigation of various total daily doses and dosage intervals
of amoxidllln In acute otitis media (AOM)
J. P. Guggenbichler, A. Regenfus
Department ofPediatrics, University ofErlangen, Germany
The proper choice of the total daily dose and dosage interval of an
antimicrobial agent i~ of crucial importance in the treument of infections
in children. For ,8-lactams, time above MIC (T > MIC) is considered as the
parameter correlating best with efficacy. The objective of this investigation
was therefore to verify whether a 2 x daily dosage regimen of amoxicillin
shows equivalent T > MIC in comparison to the presently recommended 3
x daily dosage schedule.
Multiple dose pharmacokinetic studies were performed in infants and
children with AOM after administration oft5 mg/kg BW 3 x daily versus
30 mg/kg BW twice daily. Amoxicillin plasma levels were measured with a
biological assay (double diffusion agar with B. subtilis as test organism).
With a dose of IS mg/kg BW concentrations of 14.4/-lg/rn1 ± 3.2 were
obtained after I hour. By doubling the dose to 30 mgfkg BW a concenrra-
tion of26.2 JJg/rn1 was achieved. The half-lifes ofelirnination were 1.2 h and
1.35 h respectively. Pharmacodynamic investigations ofH. injluenzae and S.
pneumoniae grown in a modified brain-heart infusion broth were performed
in a kinetic model simulating serum and tissue concentrations. Kill kinetics
and regrowth pattern were investigated with multiple doses in various
dosage intervals. Data indicate that surpassing the MIC of microorganisms
for a minimum of 75% of the dosage interval was required to achieve
adequate eradication of organisms. Eradication of organisms was achieved
with both dosage regimen in this experimental kinetic model.
T > MIC for H. inftuenzae and S. pneumoniae werc equivalent for both
dosage schedules. These data prompted us to verify the clinical efficacy and
tolerance oCan amoxicillin bid dosage regimen in children with AOM in a
randomized. comparative clinical trial.
IMo024IPharmacodynamics of tobramydn in patients with
cystic fibrosis
N.Jacobs, A. Horrevorts,]. Mouton
Department ofMedical Microbiology, CWZ, Nijmegen, Netherlands
Background: The majority ofpulmonary exacerbations due to P. aerugilUlsa
in CF will be treated with a combination ofantipseudomonal drugs. In most
cases fixed dosing regimens are used.
ObjectIves: To determine the importance oftobramycin MICs and tobra-
mycin pharmacokinetics for clinical outcome, i.e. increase in pulmonary
function.
Methods: A concentration-time curve for tobramycin was measured in 13
patients with CF (8 females/5 males; 8-20 yr) admitted to the hospital for
treatment of a pulmonary exacerbation due to P. aeruginosa. Pharrnacoki-
netic parameters of tobramycin were calculated using a tw<H:omparrrnent
open model. Pulmonary function was measured on admission and on day 10
of treatment. Tobramycin MICs against P. aeruginosa sputum isolates were
determined. Spearman'. test wa. applied to investigate the significance of
correlations between results.
Results: Increase in pulmonary function (FEVl) was correlated with Log
tobramycin AUC/tobramycin MIC ratio (r = 0.77) and with Log tobra-
mycin peak/tobramycin MIC ratio (r = 0.75), rather than with Log
tobramycin MIC (r = -0.50).
Conduslons: Tobramycin peak and/or AVC in combination with tobra-
mycin MICs are good predictive parameters for clinical outcome. If
necessary, dosing adjustment should be based on these parameters.
IMo02S1 Time to viral clearance (TVC) after experimental
influenza a infection is related to the baseline viral titer and the
plasma area under the curve of RWJ-270201
G. L. Drusanol, S. L. Prestonl, F. Hayden2,]. Treanor3, R. Qu4, L.
Gisclon4, C. Fowler4
I Albany Medical College, Albany, NY; 2Univ . of Virginia, Charlottesville,
VA; J Univ. ofRochester, Rochester, NY; 4Th R. W. Johnson Pharmaceumal
Research Institute, Raritan, Nj, United States
Objectives: We delineated the relationship between drug exposure and time
to clearance of influenza A/Texas/36/91 (HINl) in a double blind human
challenge model that examined multiple doses of R WJ-270201, a potent
inhibitor of viral neuraminidase.Methods: 90 volunteers were randomized
to receive 5 days ofplacebo or 1 of4 regimens ofRWJ-270201 (100 mg QD,
200 mg QD, 400 mg QD or 200 mg Q12 h) orally beginning 24 hours after
nasal inoculation of virus. Viral titers were determined at baseline, Q 12 h
days 1-3, then QD days 4-7. Blood samples for RWJ-270201-concentra-
tion (cone) determination were collected and cones determined by a
validated LCMS. Data were analyzed by the NPEM population-modeling
program. Baseline viral titer and R WJ-270201 !:Chedule of adminisrration,
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peak & trough cones, and AVC were examined to determine if they shifted
the hazard function for TVC in a Cox model.Results: Viral titers were
measurable in 70 subjects. TVC for 50% of the population was 85.5,78.5,
70.0,64.5 and 63.0 hn for the placebo, 100 mg QD, 200 mg QD, 400 mg QD
and 200 mg Q12 h regimens, respectively. Baseline viral titer, R WJ-270201
peak cone, trough cone, and AUC significantly affected TVC, whereas
schedule of R WJ-270201 administration did not. Only baseline viral titer
and AUC of R WJ-270201 were included in the final model.Conclusions:
R WJ-270201 and baseline viral titer significantly altered the TVC. The
schedule of administration did not affect TVC, indicating that once daily
administration ofRWJ-270201 is appropriate. This was validated by AUC
ofRWJ-270201 being chosen as the dynamically linked variable.
non-linear pharmacokinetics. There was notable inter-subject variability in
Cmax and AUCT and a low intra-subject variability. Voriconazole was well
tolerated. The most frequent treatment-related adverse events were abnor-
mal vision, headache and dizziness. Adverse events were mild and resolved
without intervention.
Conclusions: Voriconazole appeared to be well tolerated in this study. The
dosing regimens studied yielded plasma levels above in vitro MICs for
Aspergillus spp. and most emerging fungal pathogens. Further studies are
warranted to investigate the efficacy ofvoriconazole in treatment ofsystemic
fungal infections.
Table 1. Mean parameters in plasma at different doses
Table 1. Geometric means for pharmacokinetic parameters in plasma
IMo0261 Two single-blinded. p1acebo-controlled studies on
the pharmacokinetics of intravenous voriconazole - a novel
broad-spectrum antifungal agent
P. Ghahramani, L. Purkins, D. J. Nichols
jJ{izer Central ResearchUnited Kingdom
Objectives: To investigate the pharmacokinetics of voriconazole after
multiple intravenous dosing. Also, to invcstigate the effect of loading
doses of voriconazole on time to achieve steady-state concentrations.
Methods: Two single-blinded studies were performed. Study A (n = 12):
subjects received intravenous voriconazole (3 mg/kg, n = 9) or placebo (n
= 3), administered once daily on days 1 and 12, and bid on days 3 to 11.
Study B (n = 18): subjects were randomized to intravenous voriconazole (n
= 9) or placebo (n = 9), with voriconazole being administered 6 mg/kg bid
on day 1, followed by 3 mg/kg bid from day 2 to the morning of day 10.
Blood samples were collected pre-dose and up to 48 h post-dose on day 1 and
on the last day of dosing.
Results: Maximum plasma concentration (Cmax) and area under the
plasma concentration-time curve data within a dosing interval (AUCr )
are shown in Table 1. Trough concentrations ofvoriconazole at steady-state
were > 800 ng/ml which is above the in vitro MICs for most fungal
pathogens. Steady-state in study A was reached by about day 6 however in
study B it was reached within 48 h of initial dosing. In Study A, Cnux and
AUCr after multiple dosing were 3.2- and 1.7-fold higherthan that ofsingle
dose, respectively. These data are consistent with dose dependent pharma-
cokinetics.
Conclusions: The dosing regimens studied produce plasma voriconazole
concentrations above MIC90s for most fungal pathogens in vitro. Use of
loading doses (6 mg/kg bid on the first day) reduces time to achieve steady-
state levels.
Parameter
C.... (ng/ml)
AVCr (ng.h/ml)
Study A
Day 1 Day 12
2135 3621
5215 16535
Study B
Day 1 Day 10
4675 ~
13217 13245
Parameter Day Dose (mgflcg)
2 hid 40d 1.5 tid 2 tid 3 bid
Cm•• (ng/mI)· 1 485 1570 364 646 1194
12 1007 2066 1106 2184 2356
AVCr (ng h/ml). 1 1179 5896 882 1435 3145
12 4296 13185 3789 9044 11170
llf2 (h) 1 4.7 6.0 3.3 5.3 5.5
12 6.5 6.6 6.4 7.3 6.4
• Geometric mean
P:13/1 - Pharmacoanalytics and pharmacokinetics
IMoP239I A simple. High Performance liquid
Chromatography (HPLC) assay for the oxazolidinone linezolid
(LZD) in human serum
C. Tobin,J. Sunderland, L. White, A. MacGowan
BCARE, Southmead Hospital, Bristol, United Kingdom
Objectives: To develop an HPLC assay for monitoring LZD in human
serum.
Method: Stationary phase - Hypersil SODS II (10 cm x 4.6 mm); mobile
phase - 1% phosphoric acid, 30% methanol, 2 gfL heptane sulphonic acid,
adjusted to pH 5; solvent flow rate 1.0 mL/min; detection by uv absorbance
(254 nm). Sample preparation - specimen mixed 1:1 with acetonitrile and
centrifuged. Injection volume 20 1£1.
Results: The retention time of LZD was 6 min. The reproducibility was
< 6% coefficient ofvariation for a serum sample containing 2.2 mgfL LZD.
The delection limit was 0.05 mg/L. Linearity for 0, 0.1, 0.4, 0.8, 2.0 & 5.0
mg/L LZD was good for both aqueous and serum samples (r = 0.9996 and
0.9993, respectively); serum recovery approached 100% at all these con-
centrations. There was no interference from 23 commonly used antibiotics
or from 12 samples of sera from patients receiving antibiotics other than
LZD. Only benzylpenicillin resulted in low level interference (20 mg/L
equivalent to 0.35 mg/L LZD) but was easily removed by ,B-Iactamase.
ConclusIon: This rapid assay is ideally suited to the busy clinical laboratory.
IMo027! The pharmacokinetics and safety of oral
voriconazole: A novel broad-spectrum antifungal agent
P. Ghahramani, L. Purkins, M.J. Allen
Pfizer Central Research , United Kingdom
Objectives: To investigate the pharmacokinetics, safety and toleration of
voriconazole after a range of single and multiple oral doses.
Methods: This was a single-blinded, parallel group study. 64 healthy males
were randomized to voriconazole doses (mg/kg) of: 2 bid (n = 8),4 od (n =
8), 1.5 tid (n = 11), 2 tid (n = 8), 3 bid (n = 8) and placebo (n = 21).
Voriconazole was administered as single dose on days 1 and 12, and multiple
dose on days 3-11. Blood samples were collected pre-dose and up to 48 h
post-dose on days 1 and 12. Physical examination, ECG and routine clinical
laboratory tests were performed at screening, during the study and at follow
up.
Results: 56 subjects completed the study. Table 1 shows the pharmacoki-
netic parameters. Voriconazole absorption was rapid with a mean Tmax
ranging from 0.9-1.7 h across all groups. Steady-state levels were achieved
after 3-5 days of multiple dosing wirh all regimens. Voriconazole exhibited
IMoP240IQuantification of levofloxadn In bile using a HPLC
assay and a microbiological assay
S. Bottcherl , H. V. Bauml , C. Benz2, H. -G. SonntagI
1Institute ofHygiene. University ofHeidelberg; 2Dept. ofGastroentnology,
Med. Klinik C Ludwigshtifen, Germany
Objectives: This study was done to investigate the influence ofbile fluid on
two methods routinely used to determine antimicrobial agents in biological
matrices: the HPLC assay and a microbiological assay.
Methods: HPLC: A single step protein precipitation was used to isolate
Levofloxacin from the biological matrix. Levofloxacin was separated on a
C18 column and quantified by measuring the fluorescence adsorbance.
Microbiological assay: 9 mm wells were punched into IsoSensitest agar
inoculated with E. coli (ATCC 35218). Wells were filled either with sample
or calibration solution. Mter overnight culture the inhibition zones were
measured. Unknown concentrations were calculated from a calibration
curve constructed using Bennett's calculation.
Results: A good correlation between the assays was achieved [correlation
coefficient 0.959]. The slope was 0.84 ie values estimated by HLPC were
approximately 15% higher.
Using the HPLC merhod the N-oxide metabolite and the desmethyl
